Literature DB >> 8087777

The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly.

R J Havlik1, R Yancik, S Long, L Ries, B Edwards.   

Abstract

BACKGROUND: An effect of comorbidity, or the coexistence of other diseases, on the stage of cancer at diagnosis and the appropriateness of therapy in older patients with cancer is hypothesized. The effect of comorbidity differs by cancer site and by type of comorbidity. Such variation could be due to the use of different populations or methods, or the natural history of the tumor being studied.
METHODS: The National Institute on Aging (NIA) and the National Cancer Institute (NCI) have initiated a study using cancer patient populations in the NCI's SEER (Surveillance, Epidemiology and End Results) program. Five geographic locations participated in the NIA/NCI pilot study of comorbidity associated with seven cancer sites. Approximately 250 patients with each type of cancer, stratified by age (either 65-74 years of age or 75 years and older) had hospital records abstracted for comorbidity using a form derived from previously reported methods.
RESULTS: After analyzing preliminary results for 1712 patients, it was ascertained that more and different chronic disease categories would be necessary, that it was not feasible to collect data on ability to perform certain physical functions from the medical records, and that the collection of data on current medications was possible. With these limitations, relationships of comorbid conditions with stage of cancer were analyzed.
CONCLUSION: With the success of the pilot study, the full study is underway. In addition to the planned abstracting of approximately 7800 records, interviews assessing the behavior of illness in a sample of 1000 cancer patients will provide valuable information on the influence of comorbidity and age on stage at initial diagnosis and the treatment of older persons afflicted with cancer.

Entities:  

Mesh:

Year:  1994        PMID: 8087777     DOI: 10.1002/1097-0142(19941001)74:7+<2101::aid-cncr2820741718>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  32 in total

1.  Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma.

Authors:  Mario Fernández-Ruiz; Juan-Manuel Guerra-Vales; Francisco Colina-Ruizdelgado
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

2.  Evaluation of four comorbidity indices and Charlson comorbidity index adjustment for colorectal cancer patients.

Authors:  Stefano Marventano; Giuseppe Grosso; Antonio Mistretta; Marta Bogusz-Czerniewicz; Roberta Ferranti; Francesca Nolfo; Gabriele Giorgianni; Stefania Rametta; Filippo Drago; Francesco Basile; Antonio Biondi
Journal:  Int J Colorectal Dis       Date:  2014-07-27       Impact factor: 2.571

3.  The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies.

Authors:  Joseph M Unger; Elise Cook; Eric Tai; Archie Bleyer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

4.  Effectiveness of radiation therapy alone for elderly patients with unresected stage III non-small cell lung cancer.

Authors:  Keith Sigel; Linda Lurslurchachai; Marcelo Bonomi; Grace Mhango; Cara Bergamo; Minal Kale; Ethan Halm; Juan Wisnivesky
Journal:  Lung Cancer       Date:  2013-09-05       Impact factor: 5.705

Review 5.  [Radiotherapy of the elderly patient. Radiotherapy tolerance and results in older patients].

Authors:  H Geinitz; F B Zimmermann; M Molls
Journal:  Strahlenther Onkol       Date:  1999-03       Impact factor: 3.621

6.  The influence of comorbidities on overall survival among older women diagnosed with breast cancer.

Authors:  Jennifer L Patnaik; Tim Byers; Carolyn Diguiseppi; Thomas D Denberg; Dana Dabelea
Journal:  J Natl Cancer Inst       Date:  2011-06-30       Impact factor: 13.506

7.  Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas.

Authors:  Yun Fan; Neng-ming Lin; Lü-hong Luo; Luo Fang; Zhi-yu Huang; Hai-feng Yu; Feng-qin Wu
Journal:  Acta Pharmacol Sin       Date:  2011-03       Impact factor: 6.150

8.  Toxicity of initial chemotherapy in older patients with lung cancers.

Authors:  Marjorie G Zauderer; Camelia S Sima; Beatriz Korc-Grodzicki; Mark G Kris; Lee M Krug
Journal:  J Geriatr Oncol       Date:  2013-01       Impact factor: 3.599

Review 9.  Common cancers in the elderly.

Authors:  J Hansen
Journal:  Drugs Aging       Date:  1998-12       Impact factor: 3.923

10.  Colon cancer in France: evidence for improvement in management and survival.

Authors:  C Faivre-Finn; A-M Bouvier-Benhamiche; J M Phelip; S Manfredi; V Dancourt; J Faivre
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.